Answers are grounded in this paper and cite their sources.
Systematic review and meta-analysis shows moderate-to-high diagnostic performance of FGF23 in acute kidney injury, suggesting its utility as a complementary biomarker for risk stratification.
Circulating FGF23 exhibits moderate-to-high diagnostic and moderate prognostic performance in AKI, though interpretation is limited by substantial heterogeneity. It may serve as a complementary biomarker for risk stratification, pending further validation with standardized protocols.
No takes yet. Share an insight, caveat, or question.
Pei et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: